Therapeutic area

Hepatobiliary disorders – page 19

357 clinical trials
141 recruiting
239 conditions
26 countries

Clinical trials in Hepatobiliary disorders

357 trials across Europe, recruiting first

Click a country to filter the trials

Quick filters

357 clinical trials

Metabolic dysfunction-associated steatohepatitis+1

Not recruiting

Study on Efinopegdutide for Adults with Compensated Cirrhosis Due to Metabolic Dysfunction-Associated Steatohepatitis

Investigational

Study on Efinopegdutide for Adults with Compensated Cirrhosis Due to Metabolic Dysfunction-Associated Steatohepatitis

Investigational

France

Participants:18–64 years · 65+ years
Substances:Efinopegdutide
Sponsor:Merck Sharp & Dohme LLC

Contact Research Centre

B-cell lymphoma+13

Not recruiting

Study of Fadraciclib in Adults with Advanced Solid Tumors (Including Breast, Colorectal, Endometrial, Ovarian, Biliary Tract, and Liver Cancer) and Lymphoma

InvestigationalNo placebo

Study of Fadraciclib in Adults with Advanced Solid Tumors (Including Breast, Colorectal, Endometrial, Ovarian, Biliary Tract, and Liver Cancer) and Lymphoma

InvestigationalNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Fadraciclib
Sponsor:Cyclacel Limited

Contact Research Centre

B-cell lymphoma+8

Not recruiting

Study of CYC140 oral medication for patients with advanced solid tumors and lymphoma

InvestigationalNo placebo

Study of CYC140 oral medication for patients with advanced solid tumors and lymphoma

InvestigationalNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Cyc140 Monohydrochloride Monohydrate
Sponsor:Cyclacel Limited

Contact Research Centre

Hepatocellular carcinoma

Not recruiting

Study on Liver Cancer in Cirrhosis Patients Using Idarubicin and Lipiodol Injection

Registered drugNo placebo

Study on Liver Cancer in Cirrhosis Patients Using Idarubicin and Lipiodol Injection

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Ethyl Esters Of Iodised Fatty Acids From Poppyseed Oil
Sponsor:Centre Hospitalier Universitaire De Montpellier

Contact Research Centre

Cholangiocarcinoma

Not recruiting

Study of Pemigatinib for Patients with Advanced Intrahepatic Cholangiocarcinoma with FGFR2 Changes After Local Therapy

Registered drugNo placebo

Study of Pemigatinib for Patients with Advanced Intrahepatic Cholangiocarcinoma with FGFR2 Changes After Local Therapy

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Pemigatinib
Sponsor:Institut fuer Klinische Krebsforschung IKF GmbH

Contact Research Centre

Cholangitis sclerosing

Not recruiting

Study on the Safety and Effectiveness of Elafibranor for Adults with Primary Sclerosing Cholangitis

Investigational

Study on the Safety and Effectiveness of Elafibranor for Adults with Primary Sclerosing Cholangitis

Investigational

Germany

Participants:18–64 years · 65+ years
Substances:Elafibranor
Sponsor:Ipsen Bioscience Inc.

Contact Research Centre

Non-small cell lung cancer+2

Not recruiting

Study of AMG 193 alone and combined with docetaxel for treatment of advanced MTAP-null solid tumors in adult patients

InvestigationalNo placebo

Study of AMG 193 alone and combined with docetaxel for treatment of advanced MTAP-null solid tumors in adult patients

InvestigationalNo placebo

Austria

Participants:18–64 years · 65+ years
Substances:Amg 193
Sponsor:Amgen Inc.

Contact Research Centre

Cholangiocarcinoma

Not recruiting

Study Comparing Pemigatinib and Gemcitabine Plus Cisplatin for First-Line Treatment in Patients with Unresectable or Metastatic Cholangiocarcinoma with FGFR2 Rearrangement

Registered drugNo placebo

Study Comparing Pemigatinib and Gemcitabine Plus Cisplatin for First-Line Treatment in Patients with Unresectable or Metastatic Cholangiocarcinoma with FGFR2 Rearrangement

Registered drugNo placebo

Austria

Participants:18–64 years · 65+ years
Substances:Cisplatin
Sponsor:Incyte Corp.

Contact Research Centre

Erdheim-Chester disease+3

Not recruiting

Study on the Use of Fludeoxyglucose (18F) in PET/CT Scans for Young Patients with Histiocytosis

Registered drugNo placebo

Study on the Use of Fludeoxyglucose (18F) in PET/CT Scans for Young Patients with Histiocytosis

Registered drugNo placebo

Poland

Participants:0–17 years
Substances:Fludeoxyglucose (18F)
Sponsor:Instytut Matki I Dziecka

Contact Research Centre

Erdheim-Chester disease+3

Not recruiting

Study on Trametinib Dimethyl Sulfoxide for Children with Refractory Histiocytosis Not Responding to Conventional Treatment

Registered drugNo placebo

Study on Trametinib Dimethyl Sulfoxide for Children with Refractory Histiocytosis Not Responding to Conventional Treatment

Registered drugNo placebo

Poland

Participants:0–17 years
Substances:Trametinib Dimethyl Sulfoxide
Sponsor:Instytut Matki I Dziecka

Contact Research Centre

Erdheim-Chester disease+3

Not recruiting

Study on Vemurafenib for Children with BRAF Mutation-Resistant Histiocytosis

Registered drugNo placebo

Study on Vemurafenib for Children with BRAF Mutation-Resistant Histiocytosis

Registered drugNo placebo

Poland

Participants:0–17 years
Substances:Vemurafenib
Sponsor:Instytut Matki I Dziecka

Contact Research Centre

Hepatocellular carcinoma

Not recruiting

Study of Durvalumab and Tremelimumab with Y-90 SIRT for Patients with Intermediate Stage Liver Cancer

Registered drugNo placebo

Study of Durvalumab and Tremelimumab with Y-90 SIRT for Patients with Intermediate Stage Liver Cancer

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Durvalumab
Sponsor:Institut fuer Klinische Krebsforschung IKF GmbH

Contact Research Centre

Substances studied in this area

The therapies tested most often in Hepatobiliary disorders trials.

Durvalumab37 clinical trials Bevacizumab29 clinical trials Atezolizumab27 clinical trials Cisplatin26 clinical trials Lenvatinib22 clinical trials Tremelimumab22 clinical trials Gemcitabine20 clinical trials Infliximab15 clinical trials Mycophenolate Mofetil15 clinical trials

Hepatobiliary disorders – page 19

Conditions in this area

Clinical trials in Hepatobiliary disorders

357 clinical trials

Metabolic dysfunction-associated steatohepatitis+1

Study on Efinopegdutide for Adults with Compensated Cirrhosis Due to Metabolic Dysfunction-Associated Steatohepatitis

B-cell lymphoma+13

Study of Fadraciclib in Adults with Advanced Solid Tumors (Including Breast, Colorectal, Endometrial, Ovarian, Biliary Tract, and Liver Cancer) and Lymphoma

B-cell lymphoma+8

Study of CYC140 oral medication for patients with advanced solid tumors and lymphoma

Hepatocellular carcinoma

Study on Liver Cancer in Cirrhosis Patients Using Idarubicin and Lipiodol Injection

Cholangiocarcinoma

Study of Pemigatinib for Patients with Advanced Intrahepatic Cholangiocarcinoma with FGFR2 Changes After Local Therapy

Cholangitis sclerosing

Study on the Safety and Effectiveness of Elafibranor for Adults with Primary Sclerosing Cholangitis

Non-small cell lung cancer+2

Study of AMG 193 alone and combined with docetaxel for treatment of advanced MTAP-null solid tumors in adult patients

Cholangiocarcinoma

Study Comparing Pemigatinib and Gemcitabine Plus Cisplatin for First-Line Treatment in Patients with Unresectable or Metastatic Cholangiocarcinoma with FGFR2 Rearrangement

Erdheim-Chester disease+3

Study on the Use of Fludeoxyglucose (18F) in PET/CT Scans for Young Patients with Histiocytosis

Erdheim-Chester disease+3

Study on Trametinib Dimethyl Sulfoxide for Children with Refractory Histiocytosis Not Responding to Conventional Treatment

Erdheim-Chester disease+3

Study on Vemurafenib for Children with BRAF Mutation-Resistant Histiocytosis

Hepatocellular carcinoma

Study of Durvalumab and Tremelimumab with Y-90 SIRT for Patients with Intermediate Stage Liver Cancer

Filter the trials

Substances studied in this area

Prefer not to search? Our Concierge searches the trials for you.